Gearset Acquires Clayton to Strengthen Salesforce DevOps Offering
Gearset, the leader in Salesforce DevOps solutions, today announced the acquisition of Clayton, a cutting-edge code analysis platform designed specifically for Salesforce.
The strategic acquisition is Gearset’s first, following years of rapid growth fueled by a $55 million growth investment from Silversmith Capital Partners. In that time, Gearset has launched several products and upgrades, and reached the milestone of surpassing 2,500 customers — four times more than any other Salesforce DevOps vendor.
Clayton has a unique approach to Salesforce DevSecOps: identify anti-patterns and vulnerabilities early during development and remediate recurring issues with automated code corrections. Clayton has helped find and correct thousands of vulnerabilities in some of the largest Salesforce orgs on the planet.
The integration of Clayton’s technology into Gearset’s DevOps suite will enable Salesforce teams to quickly and easily build secure and well architected applications, and underscores Gearset’s commitment to delivering best-in-class solutions that optimize the entire DevOps lifecycle, from code quality to secure deployments.
Kevin Boyle, CEO at Gearset, said, “Salesforce development teams today need more than just speed — they need confidence in the quality and security of their code as they scale. The acquisition of Clayton allows us to address this need head-on by offering our customers advanced code analysis tools that streamline the development process and improve code quality from the ground up. Clayton’s deep expertise in this area aligns perfectly with our mission to empower teams with the most robust, reliable solutions available, ensuring our customers can focus on innovation for their business, while Gearset takes care of the heavy lifting in DevOps.”
Lorenzo Frattini, founder and CEO at Clayton, stated, “We started Clayton with a true passion: making it easy for teams to write secure, high-quality business apps on Salesforce. We are thrilled to join Gearset. They have built a fantastic DevOps platform that customers love. Together, we can make modern DevSecOps accessible to many more Salesforce teams, making it easier to build secure, well-architected applications at scale.”
In the immediate term, Clayton will continue to operate under its own brand within the Gearset family, ensuring uninterrupted service for existing users. As the integration of teams and technologies progresses, customers can expect a unified platform that delivers an even more powerful suite of tools to drive Salesforce DevOps success.
Financial terms of the deal were not disclosed.
About Gearset:
Gearset is the leading Salesforce DevOps platform, with powerful solutions for metadata, data and CPQ deployments, CI/CD, automated testing, sandbox seeding, archiving and backups. It helps Salesforce teams apply DevOps best practices to their development and release process, so they can rapidly and securely deliver higher-quality projects. Gearset is a uniquely reliable solution trusted by thousands of global enterprises, including McKesson, Accenture, and IBM. For more information visit www.gearset.com
About Clayton:
Clayton is the modern code analysis platform for Salesforce. It’s the only developer-first solution that catches, blocks, and automatically fixes bad code, helping you build secure and well-architected Salesforce applications fast.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240916492711/en/
Contacts
Dave Manzer
dave@growswyft.com
(512) 963-9924
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Announces US FDA Approval of ALYFTREK ™ , a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis20.12.2024 21:46:00 CET | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved ALYFTREK (vanzacaftor/tezacaftor/deutivacaftor), a once-daily next-in-class triple combination cystic fibrosis transmembrane conductance regulator (CFTR) modulator for the treatment of cystic fibrosis (CF) in people 6 years and older who have at least one F508del mutation or another mutation in the CFTR gene that is responsive to ALYFTREK. See below for Important Safety Information, including a Boxed Warning. “ALYFTREK is our fifth CFTR modulator to secure FDA approval and represents another significant milestone in our journey to serially innovate and to improve the lives of people living with cystic fibrosis,” said Reshma Kewalramani, M.D., Chief Executive Officer and President of Vertex. “Our north star for more than 20 years has been to address the underlying cause of cystic fibrosis, treat more people with this disease, and bring more people to normal le
Vertex Announces U.S. FDA Approval for TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to Include Additional Non- F508del TRIKAFTA-Responsive Variants20.12.2024 21:35:00 CET | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved the expanded use of TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for the treatment of people with cystic fibrosis (CF) ages 2 and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene or a mutation that is responsive to TRIKAFTA based on clinical and/or in vitro data. In addition, safety information on liver injury and liver failure has been updated from warnings and precautions to a boxed warning. With this approval, 94 additional non-F508delCFTR mutations have been added to the TRIKAFTA label, and approximately 300 additional people with CF in the U.S. are now eligible for a medicine to treat the underlying cause of their disease for the first time. “Since its first approval in 2019, TRIKAFTA has had a transformative impact on tens of thousands of people living with cystic fibrosis,” sai
HSBC Continental Europe Enters Into a Memorandum of Understanding Regarding Potential Sale of HSBC Assurances Vie (France) to Matmut Société d’Assurance Mutuelle20.12.2024 20:32:00 CET | Press Release
Regulatory News: HSBC Continental Europe has signed a Memorandum of Understanding (‘MOU‘) regarding the potential sale of its French life insurance business, HSBC Assurances Vie (France), to Matmut Société d’Assurance Mutuelle (‘Matmut’) (the “Potential Transaction”). HSBC Assurances Vie (France) provides a wide range of life insurance solutions and services, with over 20 billion euros of outstanding assets, net income1 of 77 million euros and a Solvency II ratio of 287% in 2023. As part of the Potential Transaction, HSBC Continental Europe and Matmut would enter into a long-term arrangement for HSBC Global Asset Management (France) to continue to partner with HSBC Assurances Vie (France). HSBC Assurances Vie (France) will continue its existing distribution arrangements. The Potential Transaction would provide customers and employees of HSBC Insurance Life (France) with the opportunity to join one of the leading French mutual insurance groups, which is in full development, and forms pa
SBC Medical Group Co., Ltd. Sells Two Subsidiaries20.12.2024 13:00:00 CET | Press Release
On December 17, 2024, SBC Medical Group Holdings Incorporated (“SBC Medical”, or the “Company”), announced that its subsidiary, SBC Medical Group Co., Ltd. (hereinafter referred to as "SBCMG"), has decided to sell all shares of its subsidiaries, SBC Kijimadaira Resort Co., Ltd. (hereinafter referred to as "Kijimadaira") and Skynet Academy Co., Ltd. (hereinafter referred to as "SNA"), as outlined below. The decision to sell these subsidiaries was made to concentrate SBCMG's management resources on its core medical services business, in line with its strategy of prioritizing and focusing on key business areas. The subsidiaries being sold operate in the following industries: Kijimadaira: Ski resort operations SNA: Flight training operations The shares will be sold to a company wholly owned by Yoshiyuki Aikawa, the CEO of the Company. Since this transaction constitutes a related party transaction, it was deliberated and approved by the Company’s Board of Directors and Audit Committee. To e
Aarhus University: New Global Study Sheds Light on the Learning Crisis: Three Years After COVID-1920.12.2024 13:00:00 CET | Press Release
TIMSS 2023 has revealed an alarming global learning crisis exacerbated by the COVID-19 pandemic. Compared to the long term trend in progress in mathematics and science achievement has not only stalled but reversed when taking school closures into account, with the most vulnerable students facing the steepest losses. Key Findings Global Achievement Decline: A 0.11 standard deviation drop in student performance reflects the pandemic's lasting impact. Disproportionate Impact: Low performers, girls, and language minorities faced losses up to twice the average (0.22 standard deviations), deepening existing inequities. Regional Variations: Countries with prolonged school closures and limited remote learning resources experienced the steepest declines. Why This Matters School closures disrupted the education of over one billion children worldwide, with disadvantaged students suffering the most. “The widening gender gap in STEM fields is particularly troubling,” said Christian Kjeldsen, incomi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom